Published in Prostate Int on May 05, 2016
Prostate cancer biomarkers: Are we hitting the mark? Prostate Int (2016) 0.77
The Non-Coding Transcriptome of Prostate Cancer: Implications for Clinical Practice. Mol Diagn Ther (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol (2014) 3.64
Cadherin switching in human prostate cancer progression. Cancer Res (2000) 2.80
Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res (2007) 2.63
Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol (2012) 2.24
Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol (2014) 1.76
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol (2014) 1.57
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol (2014) 1.30
The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am (1997) 1.29
The emerging role of extracellular vesicles as biomarkers for urogenital cancers. Nat Rev Urol (2014) 1.22
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging (2015) 1.18
New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One (2009) 1.11
Classification accuracy and cut point selection. Stat Med (2012) 1.10
Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol (1994) 1.04
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol (2016) 1.04
Abnormal prostatic cells in ejaculates from men with prostatic cancer--a preliminary report. Br J Urol (1996) 1.02
Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. J Urol (2015) 1.01
From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int (2012) 0.97
Distinct E-cadherin-based complexes regulate cell behaviour through miRNA processing or Src and p120 catenin activity. Nat Cell Biol (2015) 0.95
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis (2015) 0.93
The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am (1997) 0.91
Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer (2008) 0.89
Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol (2011) 0.88
Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate (2015) 0.86
Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocr Relat Cancer (2014) 0.83
Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82
Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PLoS One (2013) 0.82
Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. Cancer Epidemiol Biomarkers Prev (2014) 0.80
Seminal fluid: a useful source of prostate cancer biomarkers? Biomark Med (2015) 0.78